Filing Flows › Beam Therapeutics (BEAM) › Q3 2026 › vs Q2 2026
Beam Therapeutics (BEAM) Q3 2026 vs Q2 2026 (quarter over quarter)
Beam Therapeutics's revenue fell $183K (-37%) from $490K in Q2 2026 to $307K in Q3 2026.
Beam Therapeutics, Q3 2026: revenue $307K (-97% year over year), net loss $134M, operating cash flow −$111M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $307K | $490K | −$183K | -37% |
| Other income, net | $6.9M | $3.9M | $3.0M | +79% |
| Net loss | $134M | $123M | $11.7M | +10% |
| Costs & expenses | $142M | $127M | $14.6M | +11% |
| Operating costs | $142M | $127M | $14.6M | +11% |
| Research & development | $110M | $95.1M | $15.0M | +16% |
| General & admin | $31.5M | $31.9M | −$428K | -1% |
| Operating cash sources | $135M | $90.8M | $44.0M | +48% |
| Depreciation | $5.4M | $5.4M | $35K | +0.6% |
| Share-based compensation | $18.6M | $19.3M | −$723K | -4% |
| Cash used in operations | $111M | $66.1M | $44.7M | +68% |
| Net loss absorbed | $134M | $123M | $11.7M | +10% |
| Working capital & other | $343K | −$31.9M | $32.2M | — |
Questions
How much did Beam Therapeutics's revenue grow quarter over quarter in Q3 2026?
Beam Therapeutics's revenue fell $183K (-37%) from $490K in Q2 2026 to $307K in Q3 2026.